These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20632084)

  • 1. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
    Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P
    Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
    Ohno S; Rai Y; Iwata H; Yamamoto N; Yoshida M; Iwase H; Masuda N; Nakamura S; Taniguchi H; Kamigaki S; Noguchi S
    Ann Oncol; 2010 Dec; 21(12):2342-2347. PubMed ID: 20494961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
    Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
    Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
    J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant (Faslodex) -- how to make a good drug better.
    Robertson JF
    Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
    McCormack P; Sapunar F
    Clin Breast Cancer; 2008 Aug; 8(4):347-51. PubMed ID: 18757262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
    J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
    Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
    Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
    Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients.
    Warm M; Kates R; Overkamp F; Thomas A; Harbeck N
    Breast Cancer Res Treat; 2011 Jan; 125(1):127-36. PubMed ID: 20960229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
    Robertson JF; Erikstein B; Osborne KC; Pippen J; Come SE; Parker LM; Gertler S; Harrison MP; Clarke DA
    Clin Pharmacokinet; 2004; 43(8):529-38. PubMed ID: 15170367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
    Hyams DM; Chan A; de Oliveira C; Snyder R; Vinholes J; Audeh MW; Alencar VM; Lombard J; Mookerjee B; Xu J; Brown K; Klein P
    Invest New Drugs; 2013 Oct; 31(5):1345-54. PubMed ID: 23801303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.